

March 25, 2019

Via E-mail: AGO.highcostprescriptiondrugs@vermont.gov

Re: Notice of New Drug Introduction Pursuant to 18 V.S.A. § 4637

To Whom It May Concern:

Teva Pharmaceuticals USA, Inc. (“Teva”) submits this information pursuant to 18 V.S.A. § 4637(b). On March 22, 2019, Teva released the following generic prescription drug to the commercial market:

<b>NDC</b>	<b>Product Description</b>	<b>WAC</b>
45963-0454-30	DEFERASIROX 125MG TABLETS 30	\$750.99
45963-0455-30	DEFERASIROX 250MG TABLETS 30	\$1,501.95
45963-0456-30	DEFERASIROX 500MG TABLETS 30	\$3,003.84

Teva provides this notice consistent with its understanding and interpretation of 18 V.S.A. § 4637 and its provisions. In providing this notice, Teva does not waive any rights it may have at law or in equity with respect to 18 V.S.A. § 4637, its interpretation, and/or its application to Teva or any of its affiliates, now or in the future. Teva, on behalf of itself and its affiliates, expressly reserves all such rights.

Thank you for your consideration.

Sincerely,



Brian Savage  
General Counsel, US Generics  
Teva Pharmaceuticals USA, Inc.